Clinical Trial Detail

NCT ID NCT04211337
Title A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

thyroid gland medullary carcinoma

Therapies

Vandetanib

Cabozantinib

Selpercatinib

Age Groups: adult senior

Additional content available in CKB BOOST